Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Callum Baird NattressCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0001-9326-3632
Rhianna O'SullivanCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0009-0005-6128-7601
Daniel FowlerInnate Immune Engineering Laboratory, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0002-0966-0983
Colin HuttonStem Cell and Cancer Biology Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2254-1038
Petra VlckovaCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0001-9633-8492
Jahangir SufiCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-4563-5531
Magdalena BuschhausAntibody Medicines Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-5705-8997
Ewa BasiarzCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-2048-954X
Maria Ramos ZapateroCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0003-3873-5347
Ferran Cardoso RodriguezCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-1376-1242
Xiao QinCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-8738-4187
Ashley CampbellCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0003-3604-6935
Angeliki KanoutaInnate Immune Engineering Laboratory, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0009-0007-4742-7350
Vivian S W LiStem Cell and Cancer Biology Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2041-0085
Kerry ChesterAntibody Medicines Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0002-3093-3130
John AndersonDepartment of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Great Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0001-7509-3203
Marta BarisaInnate Immune Engineering Laboratory, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0001-7846-6810
Jonathan P H FisherInnate Immune Engineering Laboratory, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0003-3302-2241
Christopher J TapeCell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom.ORCID 0000-0003-4712-2737
Funding
Academy of Medical Sciences (The Academy of Medical Sciences) SGL024/1022Cancer Research UK (CRUK) C355/A28852Cancer Research UK (CRUK) C60693/A23783Cancer Research UK (CRUK) C7893/A26233Cancer Research UK (CRUK) CTRQQR-2021\100004EPA EP-C-18-007Great Ormond Street Hospital Charity (GOSH) VS0119Little Princess Trust (LPT) CCLGA 2021 14 FisherMedical Research Council (MRC) MR/T028270/1National Institute for Health and Care Research (NIHR) CL-2019-18-007UCLH Biomedical Research Centre (UCL) BRC422University College London (UCL) UTF-20-006/Fisher/UCLWellcome TrustWellcome Trust (WT) 214046/Z/18/Z
6 · The paper itself
Abstract
γδ T cells can kill cancer cells via antibody-independent cytotoxicity (AIC) and antibody-dependent cellular cytotoxicity (ADCC). A better understanding of how these cytotoxic mechanisms are affected by different cancer cells and different T-cell donors could help identify improved immunotherapeutic strategies. To test the combinatorial interactions among T cell interdonor heterogeneity, cancer cell intertumor heterogeneity (ITH), and multimodal γδ T-cell killing, we performed a systematic single-cell phenoscaping analysis of more than 1,000 γδ T-cell and colorectal cancer patient-derived organoid cultures. Single-cell analysis of posttranslational modification (PTM) signaling, cell cycle, apoptosis, and T-cell immunophenotypes revealed that whereas unmodified γδ T cells have limited antitumor activity, IL15Rα-IL15 fusion protein [stabilized IL15 (stIL15)]-engineered γδ T cells can kill patient-derived organoids via AIC without exogenous cytokine support. However, when stIL15 γδ T cells only killed via AIC, cancer cells reciprocally rewired γδ T-cell PTM signal networks in an ITH-specific manner to suppress anticancer cytotoxicity. stIL15 γδ T cells could overcome this cancer cell immunomodulation by also engaging B7-H3-targeted ADCC independent of B7-H3 checkpoint activity. Combined AIC and ADCC rescued γδ T-cell PTM signaling flux and enabled γδ T cells to kill chemorefactory revival colon cancer stem cells. Together, these results demonstrate that multimodal γδ T-cell cytoxicity mechanisms can overcome ITH-specific immunomodulation to kill chemorefractory cancer cells. SIGNIFICANCE: Single-cell phenoscaping of more than 1,000 γδ T-cell and patient-derived organoid cultures shows that cancer cells suppress anticancer γδ T-cell cytotoxicity but γδ T cells can use multimodal killing to overcome immunomodulation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell-Mediated Immunomodulation. · full record | OpenQuestion